-
Cogent Biosciences Inc NASDAQ:COGT Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.
Location: | Website: www.cogentbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.082B
Cash
363.2M
Avg Qtr Burn
-44.32M
Short % of Float
12.21%
Insider Ownership
0.13%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib Details Cancer, Gastrointestinal stromal tumors | Phase 3 Data readout | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Systemic Mastocytosis | Phase 2 Data readout | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Nonadvanced systemic mastocytosis | Phase 2 Data readout | |
CGT4255 / CNS-penetrant ErbB2 program Details Solid tumor/s | IND Submission |